• Max Marsden, Robert Lendrum, and Ross Davenport.
• Centre for Trauma Sciences, Blizard Institute, Queen Mary University of London, UK.
• Curr Opin Crit Care. 2023 Dec 1; 29 (6): 689695689-695.

Purpose Of ReviewThe use of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) to temporarily control bleeding and improve central perfusion in critically injured trauma patients remains a controversial topic. In the last decade, select trauma services around the world have gained experience with REBOA. We discuss the recent observational data together with the initial results of the first randomized control trial and provide a view on the next steps for REBOA in trauma resuscitation.Recent FindingsWhile the observational data continue to be conflicting, the first randomized control trial signals that in the UK, in-hospital REBOA is associated with harm. Likely a result of delays to haemorrhage control, views are again split on whether to abandon complex interventions in bleeding trauma patients and to only prioritize transfer to the operating room or to push REBOA earlier into the post injury phase, recognizing that some patients will not survive without intervention.SummaryBetter understanding of cardiac shock physiology provides a new lens in which to evaluate REBOA through. Patient selection remains a huge challenge. Invasive blood pressure monitoring, combined with machine learning aided decision support may assist clinicians and their patients in the future. The use of REBOA should not delay definitive haemorrhage control in those patients without impending cardiac arrest.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

28 keywords...

hide…